Aurinia Pharmaceuticals Inc. cotiza a 16.55 USD y tiene una capitalización bursátil de $2.2B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. I…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.28 | $0.25 | $1.53 |
| Estimado | $0.22 | $0.24 | $0.20 | $0.22 |
| Sorpresa | — | +16.7% | +25.0% | +595.5% |
| Métrica | AUPH | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 88.5% | 57.0% | +31.4% |
| Operating Margin | 37.1% | -38.6% | +75.7% |
| Net Margin | 101.5% | -33.6% | +135.0% |
| FCF Margin | — | -13.9% | — |
| ROE | 49.4% | -40.4% | +89.8% |
| ROA | 38.2% | -32.0% | +70.2% |
| Current Ratio | 5.25 | 2.84 | +2.41 |
| Debt / Equity | — | 0.28 | — |